Article
TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors.
International journal of cancer - 1 Nov 2009
Oikonomou Eftychia, Kosmidou Vivian, Katseli Anastasia, Kothonidis Konstantinos, Mourtzoukou Despina, Kontogeorgos George, Andera Ladislav, Zografos Georgios, Pintzas Alexander
Abstract excerpt
TRAIL raises hopes as a promising anti-tumor agent due to its selectivity toward cancer cells. Higher expression of its pro-death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) attenuates higher sensitivity to TRAIL-induced apoptosis, and represents a marker for better cancer prognosis and treatment. Since receptor availability can be analogous to ligand efficacy, we performed RT-PCR analysis of DR4 and DR5 in 51...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
